United Kingdom (UK): pharmaceutical products import value from the EU 2012-2018
In 2018, the United Kingdom imported over 23.7 billion U.S. billion dollars’ worth of pharmaceutical products from the rest of the European Union. This is a decrease from the preceding year, and even further down from the peak import value in this time period of approximately 27.4 billion U.S. dollars in 2014.
Which countries are the products coming from?
Of the EU, the Netherlands had the highest value of pharmaceutical products imported into the UK, amounting to over 4.6 billion British pounds in 2018. Followed by Germany at approximately 3.5 billion British pounds. The UK had a negative trade balance with the Netherlands of over three billion British pounds, which means the UK imports a considerable amount more pharmaceutical goods from there than it exports.
Impact of Brexit
In a 2018 survey of EU influencers, 32 percent believed that EU pharmaceutical companies will be negatively affected by Brexit, while 41 percent believes that trade barriers will potentially impact the supply of medicines. Additionally, another survey of pharmaceutical industry board level executives revealed that half of those question indicated that Brexit had impacted on the attractiveness of the UK pharmaceutical market.
Which countries are the products coming from?
Of the EU, the Netherlands had the highest value of pharmaceutical products imported into the UK, amounting to over 4.6 billion British pounds in 2018. Followed by Germany at approximately 3.5 billion British pounds. The UK had a negative trade balance with the Netherlands of over three billion British pounds, which means the UK imports a considerable amount more pharmaceutical goods from there than it exports.
Impact of Brexit
In a 2018 survey of EU influencers, 32 percent believed that EU pharmaceutical companies will be negatively affected by Brexit, while 41 percent believes that trade barriers will potentially impact the supply of medicines. Additionally, another survey of pharmaceutical industry board level executives revealed that half of those question indicated that Brexit had impacted on the attractiveness of the UK pharmaceutical market.
